OncoMatch/Clinical Trials/NCT06780085
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Is NCT06780085 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: Raludotatug Deruxtecan · Ifinatamab Deruxtecan · Docetetaxel · 5-hydroxytryptamine subtype 3 receptor antagonist · Neurokinin-1 receptor antagonist · Corticosteroid — Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
disease progression per RECIST 1.1 after receiving an anti-programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) treatment
Must have received: platinum-based chemotherapy
disease progression per RECIST 1.1 after receiving ... platinum-based chemotherapy
Cannot have received: docetaxel (docetaxel)
Has previously received docetaxel as monotherapy or in combination with other therapies
Cannot have received: radiation therapy
Received radiation therapy to the lung
Lab requirements
Blood counts
Has adequate organ function
Kidney function
Has adequate organ function
Liver function
Has adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kentucky Chandler Medical Center ( Site 0019) · Lexington, Kentucky
- MedStar Franklin Square Medical Center ( Site 0033) · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify